Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02514681
Recruitment Status : Unknown
Verified April 2017 by Japan Breast Cancer Research Group.
Recruitment status was:  Recruiting
First Posted : August 4, 2015
Last Update Posted : April 19, 2017
Sponsor:
Collaborator:
Chugai Pharmaceutical
Information provided by (Responsible Party):
Japan Breast Cancer Research Group

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer patients for previously treated with pertuzumab

Condition or disease Intervention/treatment Phase
HER2-positive Locally Advanced or Metastatic Breast Cancer Drug: Trastuzumab Drug: Pertuzumab Drug: Docetaxel Drug: Paclitaxel Drug: Nab-paclitaxel Drug: Vinorelbine Drug: Eribulin Drug: Capecitabine Drug: Gemcitabine Phase 3

Detailed Description:

The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines recommend the use of pertuzumab, trastuzumab and taxane as first-line treatment for patients with MBC. As a second-line treatment, trastuzumab emtansine (T-DM1) is also recommended. After a pertuzumab-containing regimen and T-DM1, other HER2-targeted therapeutic regimens, including lapatinib-containing regimens and trastuzumab plus chemotherapy, are recommended as third-line treatments and beyond. However, continual pertuzumab use for progression after a pertuzumab-containing regimen and retreatment with pertuzumab are unclear based on evidence.

The efficacy and the safety of two distinct modalities of a trastuzumab plus pertuzumab-containing regimen after pertuzumab use should be assessed in MBC: continual treatment and retreatment. However, it is clinically difficult to examine the efficacy of continual treatment with a trastuzumab plus pertuzumab-containing regimen because of several circumstances including the results of the MARIANNE study.

In addition, it is also important to evaluate the usefulness of retreatment with a pertuzumab-containing regimen. Continual pertuzumab treatment for progression after pertuzumab treatment is not same as pertuzumab retreatment. HER2-HER3-signaling suppressed by pertuzumab-containing regimens could potentially be restored by anti-HER2 therapy without pertuzumab. Pertuzumab retreatment could potentially re-suppress HER2-HER3-signaling. Therefore, Pertuzumab retreatment can be more effective than trastuzumab-containing treatment without pertuzumab.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 370 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer
Actual Study Start Date : October 2015
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Pertuzumab

Arm Intervention/treatment
Active Comparator: Trastuzumab + chemotherapy
Trastuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel ,Vinorelbine, Eribulin, Capecitabine or Gemcitabine
Drug: Trastuzumab
Other Name: Herceptin

Drug: Docetaxel
Other Name: Taxotere

Drug: Paclitaxel
Other Name: Taxol

Drug: Nab-paclitaxel
Other Name: Abraxane

Drug: Vinorelbine
Other Name: Navelbine

Drug: Eribulin
Other Name: Halaven

Drug: Capecitabine
Other Name: Xeloda

Drug: Gemcitabine
Other Name: Gemzar

Experimental: Trastuzumab+ pertuzumab + chemotherapy
Trastuzumab+ pertuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine or Gemcitabine
Drug: Trastuzumab
Other Name: Herceptin

Drug: Pertuzumab
Other Name: Perjeta

Drug: Docetaxel
Other Name: Taxotere

Drug: Paclitaxel
Other Name: Taxol

Drug: Nab-paclitaxel
Other Name: Abraxane

Drug: Vinorelbine
Other Name: Navelbine

Drug: Eribulin
Other Name: Halaven

Drug: Capecitabine
Other Name: Xeloda

Drug: Gemcitabine
Other Name: Gemzar




Primary Outcome Measures :
  1. Progression-free survival (assessed by investigators) [ Time Frame: 4 years ]

Secondary Outcome Measures :
  1. Progression-free survival (assessed by independent review) [ Time Frame: 4 years ]
  2. PFS in patients treated with trastuzumab emtansine (T-DM1) as the latest regimen [ Time Frame: 4 years ]
  3. Response rate [ Time Frame: 4 years ]
  4. Duration of response, Overall survival [ Time Frame: 4 years ]
  5. Patient-reported-outcome [ Time Frame: 4 years ]
    Difference in terms of patient-reported outcome (PRO) between standard group and Pertuzumab treated group FACT-G, FACT-B and EQ-5D are used as assessment tools for PRO.

  6. Safety assessed by Incidence/Grade of Serious Adverse Events (SAEs), Pertuzumab-specific adverse events, laboratory abnormalities Percentage and number of subjects who discontinued for adverse event. [ Time Frame: 4 years ]
    Safety for HER2-positive locally advanced or metastatic breast cancer subjects who were previously treated with Pertuzumab

  7. Biomarkers [ Time Frame: 4 years ]
    To find Prognostic and predictive biomarker markers for patients receiving anti-HER2 treatment. Changes in immunologic markers on peripheral blood mononuclear cells determined by flow cytometry after anti-HER2 treatment Changes in tumor-derived gene mutations (e.g. PIK3CA, APOBEC3, CDH1…etc.) in ctDNA after anti-HER2 therapy Changes in proteins (e.g. HER2, HER3…etc.) and micro RNAs expression in extracellular vesicle after anti-HER2 therapy Changes in glycans and proteins expression in the plasma after anti-HER2 therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed invasive breast cancer
  2. A confirmed HER2-positive status assessed by means of immunohistochemical analysis (with 3+ indicating positive status) and/or in situ hybridization (with an amplification ratio > 2.0 indicating positive) by each institute
  3. History of pertuzumab and trastuzumab-containing chemotherapy for locally advanced and metastatic breast cancer(2 or 3 regimen as previous chemotherapy regimen for locally advanced or metastatic breast cancer). The latest regimen before enrollment dose not include pertuzumab.
  4. Patients have measurable and/or non-measurable disease according to RECIST ver1.1.
  5. Female patients and aged ≥ 20 years.
  6. Left Ventricular Ejection Fraction (LVEF) > 50% at baseline (within 28 days before enrollment) as determined by either ECHO or MUGA
  7. Eastern Cooperative Oncology Group performance status of 0,1 or 2.
  8. Life expectancy of patients is expected at least 3 months.
  9. Signed and written informed consent (approved by the Institutional Review Board or Independent Ethics Committee) is obtained before any study procedure.

Exclusion Criteria:

  1. History of chemotherapy > 4 regimen for locally advance or metastatic disease except for cancer chemotherapeutic agent-free treatment regimen (eg, hormonal therapy alone, combination with hormonal therapy and trastuzumab and anti-HER2 therapy alone).
  2. Persistent Grade >3 non-hematologic toxicity according to NCI-CTCAE v4.0-JCOG resulting from previous therapy at the time of enrollment.
  3. Symptomatic or uncontrolled central nervous system metastases.
  4. Multiple malignancies without history of breast cancer(within 10 years if invasive breast cancer and within 5 years if malignancies except invasive breast cancer)
  5. History of exposure to the following cumulative doses of anthracyclines:

    • doxorubicin or liposomal doxorubicin > 360 mg/m2
    • epirubicin > 720 mg/m2
    • mitoxantrone > 100 mg/m2
    • If more than 1 anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.
  6. Current uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg) or unstable angina.
  7. History of CHF of any New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment (exception, atrial fibrillation, paroxysmal supraventricular tachycardia).
  8. History of myocardial infarction within 6 months of enrollment.
  9. Dyspnea at rest due to complications of advanced malignancy.
  10. Inadequate organ function, as determined by the following laboratory results, within 28 days before enrollment:

    • Absolute neutrophil count < 1,500/mm3
    • Platelet count < 100,000/mm3
    • Hemoglobin < 8.0 g/dL
    • Total bilirubin > 2.0 mg/dL, unless the patient has documented Gilbert's syndrome
    • Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 100IU /L with the following exception (If considered that the liver dysfunction due to liver metastases > 200 IU/L, or 100 < , ≤200 IU/L with serum albumin < 2.5 g/dL)
    • Serum creatinine value > 2.0 mg/dL or 177 μmol/L
  11. Current severe uncontrolled systemic disease(eg. Clinically significant cardiovascular, pulmonary and metabolic disease*, disorder of wound healing, ulcer and fracture)

    *If gemcitabine is planned to be selected as a combination chemotherapeutic agent,patients who has symptomatic interstitial pneumonia or pulmonary fibrosis on chest X-ray should be excluded.

  12. Uncontrolled malignancy-associated hypercalcemia syndrome under bisphosphonates or denosumab treatment.
  13. Radiation related grade >2 adverse event within 14 days before enrollment.
  14. Major surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of need for major surgery during the course of study treatment.
  15. Pregnant woman or positive pregnancy test.
  16. Nursing woman
  17. History of receiving any investigational treatment within 28 days before enrollment.
  18. Current known and active infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus.
  19. Receipt of intravenous antibiotics for infection within 14 days before enrollment.
  20. Current chronic daily treatment (continuous for > 3 months) with corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids.
  21. Known hypersensitivity to pertuzumab or trastuzumab without infusion reaction related to these drugs
  22. Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02514681


Contacts
Layout table for location contacts
Contact: Yutaka Yamamoto, MD, PhD +81-96-373-5521 ys-yama@triton.ocn.ne.jp

Locations
Layout table for location information
Japan
Aichi Cancer Center Hospital Recruiting
Chikusa-ku, Aichi, Japan, 4648681
Contact: Hiroji Iwata, MD, PhD    +81-52-762-6111      
Principal Investigator: Hiroji Iwata, MD, PhD         
Kumamoto University Hospital Recruiting
Kumamoto City, Kumamoto, Japan, 8608556
Contact: Yutaka Yamamoto, MD, PhD    +81-96-373-5521      
Principal Investigator: Yutaka Yamamoto, MD, PhD         
Japan Breast Cancer Research Group Recruiting
Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan, 1030016
Contact    +81-3-6264-8873    office@jbcrg.jp   
Sponsors and Collaborators
Japan Breast Cancer Research Group
Chugai Pharmaceutical
Investigators
Layout table for investigator information
Principal Investigator: Hiroji Iwata, MD, PhD Aichi Cancer Center Hospital
Principal Investigator: Yutaka Yamamoto, MD, PhD Kumamoto University Hospital

Publications:

Layout table for additonal information
Responsible Party: Japan Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT02514681     History of Changes
Other Study ID Numbers: JBCRG-M05
First Posted: August 4, 2015    Key Record Dates
Last Update Posted: April 19, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pertuzumab
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Gemcitabine
Paclitaxel
Vinorelbine
Docetaxel
Albumin-Bound Paclitaxel
Capecitabine
Trastuzumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological